Immunome Inc (NASDAQ:IMNM) — Market Cap & Net Worth
Market Cap & Net Worth: Immunome Inc (IMNM)
Immunome Inc (NASDAQ:IMNM) has a market capitalization of $2.03 Billion ($2.03 Billion) as of June 17, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #6283 globally and #1932 in its home market, demonstrating a -3.76% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Immunome Inc's stock price $17.91 by its total outstanding shares 113249519 (113.25 Million). Review Immunome Inc (IMNM) financial obligations to assess the company's total debt and financial obligations.
Immunome Inc Market Cap History: 2020 to 2026
Immunome Inc's market capitalization history from 2020 to 2026. Data shows growth from $1.10 Billion to $2.03 Billion (5.15% CAGR).
Index Memberships
Immunome Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.43 Trillion | 0.08% | #152 of 976 |
|
NASDAQ Composite
IXIC
|
$41.27 Trillion | 0.00% | #685 of 3165 |
Weight: Immunome Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Immunome Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Immunome Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
350.47x
Immunome Inc's market cap is 350.47 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2022 | $250.28 Million | $6.63 Million | -$36.90 Million | 37.77x | N/A |
| 2023 | $1.21 Billion | $14.02 Million | -$106.81 Million | 86.44x | N/A |
| 2024 | $1.20 Billion | $9.04 Million | -$292.96 Million | 133.03x | N/A |
| 2025 | $2.43 Billion | $6.94 Million | -$212.39 Million | 350.47x | N/A |
Competitor Companies of IMNM by Market Capitalization
Companies near Immunome Inc in the global market cap rankings as of June 17, 2026.
Key companies related to Immunome Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #222 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #442 globally with a market cap of $63.33 Billion USD.
- UCB SA (BR:UCB): Ranked #550 globally with a market cap of $49.68 Billion USD ( €42.50 Billion EUR).
- Argen-X (BR:ARGX): Ranked #574 globally with a market cap of $47.14 Billion USD ( €40.32 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #222 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $453.17 |
| #442 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $63.33 Billion | $614.73 |
| #550 | UCB SA | BR:UCB | $49.68 Billion | €250.00 |
| #574 | Argen-X | BR:ARGX | $47.14 Billion | €755.80 |
Immunome Inc Historical Marketcap From 2020 to 2026
Between 2020 and today, Immunome Inc's market cap moved from $1.10 Billion to $ 2.03 Billion, with a yearly change of 5.15%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $2.03 Billion | -16.62% |
| 2025 | $2.43 Billion | +102.26% |
| 2024 | $1.20 Billion | -0.75% |
| 2023 | $1.21 Billion | +384.16% |
| 2022 | $250.28 Million | -82.95% |
| 2021 | $1.47 Billion | +33.88% |
| 2020 | $1.10 Billion | -- |
End of Day Market Cap According to Different Sources
On Jun 17th, 2026 the market cap of Immunome Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $2.03 Billion USD |
| MoneyControl | $2.03 Billion USD |
| MarketWatch | $2.03 Billion USD |
| marketcap.company | $2.03 Billion USD |
| Reuters | $2.03 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Immunome Inc
Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States. The company develops clinical asset comprising Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine… Read more